IL-15-PI3K-AKT-mTOR: A critical pathway in the life journey of Natural Killer cells

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages 1-22

  Ali, Alaa Kassim ^a   Nandagopal, Neethi ^a,b   Lee, Seung Hwan ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

AKT; Effector functions; IL 15; mTOR; Natural killer cells; PI3K; Proliferation; Virus infection

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; EOMESODERMIN; GAMMA INTERFERON; GUANOSINE TRIPHOSPHATASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 21; INTERLEUKIN 4; JANUS KINASE 1; JANUS KINASE 3; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN P85; S6 KINASE; STAT PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5B PROTEIN; TRIPHOSPHOINOSITIDE; TUBERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2 MORPHOLINO 8 PHENYLCHROMONE; BROXURIDINE; CD71 ANTIGEN; CD98 ANTIGEN; GRANZYME B; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 5; STAT5 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING;

AMNESIA; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL EXPANSION; CELL PROLIFERATION; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; GENE EXPRESSION; GENE MUTATION; GLYCOLYSIS; HUMAN; IMMUNOMODULATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; LYMPHOID PROGENITOR CELL; NATURAL KILLER CELL; NONHUMAN; ONCOGENE C MYC; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; HANTAVIRUS; LYMPHOCYTE TRANSFORMATION; MURINE CYTOMEGALOVIRUS; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL; VIRUS INFECTION;

EID: 84935099494     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00355     Document Type: Review

References (100)

1. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annual Review of Immunology (1999) 17:189. PubMed PMID: 41.
2. Lee SH, Miyagi T, Biron CA. Keeping NK cells in highly regulated antiviral warfare. Trends Immunol (2007) 28(6):252-9. Epub 2007/05/01. doi: S1471-4906(07)00081-6 [pii] 10.1016/j.it.2007.04.001. PubMed PMID: 17466596.
3. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol (2008) 9(5):503-10. doi: 10.1038/ni1582. PubMed PMID: 18425107.
4. Kiessling R, Petranyi G, Karre K, Jondal M, Tracey D, Wigzell H. Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. The Journal of experimental medicine (1976) 143(4):772-80. Epub 1976/04/01. PubMed PMID: 1082915; PubMed Central PMCID: PMC2190156.
5. Herberman RB, Nunn ME, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer (1975) 16(2):216-29. Epub 1975/08/15. PubMed PMID: 50294.
6. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol (2008) 9(5):495-502. Epub 2008/04/22. doi: ni1581 [pii] 10.1038/ni1581. PubMed PMID: 18425106.
7. Degli-Esposti MA, Smyth MJ. Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat Rev Immunol (2005) 5(2):112-24. doi: 10.1038/nri1549. PubMed PMID: 15688039.
8. Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (2014) 2014:205796. doi: 10.1155/2014/205796. PubMed PMID: 25054077; PubMed Central PMCID: PMC4099226.
9. Marcais A, Viel S, Grau M, Henry T, Marvel J, Walzer T. Regulation of mouse NK cell development and function by cytokines. Front Immunol (2013) 4:450. doi: 10.3389/fimmu.2013.00450. PubMed PMID: 24376448; PubMed Central PMCID: PMC3859915.
10. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annual review of immunology (2006) 24:657-79. Epub 2006/03/23. doi: 10.1146/annurev.immunol.24.021605.090727. PubMed PMID: 16551262.
11. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol (2006) 6(8):595-601. doi: 10.1038/nri1901. PubMed PMID: 16868550.
12. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood (2006) 107(6):2409-14. doi: 10.1182/blood-2005-06-2399. PubMed PMID: 16304057; PubMed Central PMCID: PMC1473973.
13. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 365(22):2055-66. doi: 10.1056/NEJMoa1108188. PubMed PMID: 22129252; PubMed Central PMCID: PMC3727432.
14. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood (2006) 108(5):1571-9. doi: 10.1182/blood- 2006-02-004747. PubMed PMID: 16645171; PubMed Central PMCID: PMC1895505.
15. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood (2009) 114(12):2417-26. doi: 10.1182/blood-2008-12-189266. PubMed PMID: 19605850; PubMed Central PMCID: PMC2746471.
16. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. The Journal of experimental medicine (2000) 191(5):771-80. Epub 2000/03/08. PubMed PMID: 10704459; PubMed Central PMCID: PMC2195858.
17. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood (2001) 97(1):14-32. Epub 2001/01/03. PubMed PMID: 11133738.
18. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol (2004) 173(6):3594-8. Epub 2004/09/10. PubMed PMID: 15356102.
19. Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity (2002) 17(5):537-47. Epub 2002/11/16. PubMed PMID: 12433361.
20. Kovanen PE, Leonard WJ. Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev (2004) 202:67-83. Epub 2004/11/18. doi: 10.1111/j.0105-2896.2004.00203.x. PubMed PMID: 15546386.
21. Eckelhart E, Warsch W, Zebedin E, Simma O, Stoiber D, Kolbe T, et al. A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood (2011) 117(5):1565-73. Epub 2010/12/04. doi: 10.1182/blood-2010-06-291633. PubMed PMID: 21127177.
22. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, et al. Stat5 is required for IL-2- induced cell cycle progression of peripheral T cells. Immunity (1999) 10(2):249-59. Epub 1999/03/11. PubMed PMID: 10072077.
23. Imada K, Bloom ET, Nakajima H, Horvath-Arcidiacono JA, Udy GB, Davey HW, et al. Stat5b is essential for natural killer cell-mediated proliferation and cytolytic activity. The Journal of experimental medicine (1998) 188(11):2067-74. Epub 1998/12/08. PubMed PMID: 9841920; PubMed Central PMCID: PMC2212377.
24. Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, et al. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics (2006) 118(5):e1584-92. Epub 2006/10/13. doi: 10.1542/peds.2005-2882. PubMed PMID: 17030597.
25. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol (2013) 31:675-704. doi: 10.1146/annurev-immunol-032712-095946. PubMed PMID: 23330955.
26. Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol (2013) 4:20. doi: 10.3389/fimmu.2013.00020. PubMed PMID: 23378844; PubMed Central PMCID: PMC3561661.
27. Oak JS, Fruman DA. Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity (2007) 40(6):433-41. doi: 10.1080/08916930701464780. PubMed PMID: 17729037.
28. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307(5712):1098-101. doi: 10.1126/science.1106148. PubMed PMID: 15718470.
29. Yang K, Neale G, Green DR, He W, Chi H. The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol (2011) 12(9):888-97. doi: 10.1038/ni.2068. PubMed PMID: 21765414; PubMed Central PMCID: PMC3158818.
30. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell (2012) 149(2):274-93. Epub 2012/04/17. doi: 10.1016/j.cell.2012.03.017. PubMed PMID: 22500797; PubMed Central PMCID: PMC3331679.
31. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes & development (2003) 17(15):1829-34. doi: 10.1101/gad.1110003. PubMed PMID: 12869586; PubMed Central PMCID: PMC196227.
32. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Molecular cell (2007) 25(6):903-15. doi: 10.1016/j.molcel.2007.03.003. PubMed PMID: 17386266.
33. Huang K, Fingar DC. Growing knowledge of the mTOR signaling network. Seminars in cell & developmental biology (2014) 36:79-90. doi: 10.1016/j.semcdb.2014.09.011. PubMed PMID: 25242279; PubMed Central PMCID: PMC4253687.
34. Di Santo JP. Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol (2006) 24:257-86. doi: 10.1146/annurev.immunol.24.021605.090700. PubMed PMID: 16551250.
35. Huntington ND, Vosshenrich CA, Di Santo JP. Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol (2007) 7(9):703-14. doi: 10.1038/nri2154. PubMed PMID: 17717540.
36. Rosmaraki EE, Douagi I, Roth C, Colucci F, Cumano A, Di Santo JP. Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol (2001) 31(6):1900-9. doi: 10.1002/1521-4141(200106)31:6<1900::AID-IMMU1900>3.0.CO;2-M. PubMed PMID: 11433387.
37. Male V, Brady HJ. Transcriptional control of NK cell differentiation and function. Current topics in microbiology and immunology (2014) 381:173-87. doi: 10.1007/82_2014_376. PubMed PMID: 24850220.
38. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol (2005) 6(12):1236-44. doi: 10.1038/ni1268. PubMed PMID: 16273099.
39. Kamizono S, Duncan GS, Seidel MG, Morimoto A, Hamada K, Grosveld G, et al. Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med (2009) 206(13):2977-86. doi: 10.1084/jem.20092176. PubMed PMID: 19995955; PubMed Central PMCID: PMC2806474.
40. Male V, Nisoli I, Kostrzewski T, Allan DS, Carlyle JR, Lord GM, et al. The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression. J Exp Med (2014) 211(4):635-42. doi: 10.1084/jem.20132398. PubMed PMID: 24663216; PubMed Central PMCID: PMC3978281.
41. Yang M, Li D, Chang Z, Yang Z, Tian Z, Dong Z. PDK1 orchestrates early NK cell development through induction of E4BP4 expression and maintenance of IL-15 responsiveness. J Exp Med (2015) 212(2):253-65. doi: 10.1084/jem.20141703. PubMed PMID: 25624444; PubMed Central PMCID: PMC4322053.
42. Marcais A, Cherfils-Vicini J, Viant C, Degouve S, Viel S, Fenis A, et al. The metabolic checkpoint kinase mTOR is essential for IL-15 signaling during the development and activation of NK cells. Nat Immunol (2014) 15(8):749-57. doi: 10.1038/ni.2936. PubMed PMID: 24973821; PubMed Central PMCID: PMC4110708.
43. Tassi I, Cella M, Gilfillan S, Turnbull I, Diacovo TG, Penninger JM, et al. p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity (2007) 27(2):214-27. doi: 10.1016/j.immuni.2007.07.014. PubMed PMID: 17723215.
44. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity (2007) 26(4):503-17. Epub 2007/04/03. doi: 10.1016/j.immuni.2007.03.006. PubMed PMID: 17398124; PubMed Central PMCID: PMC2084390.
45. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol (1999) 162(8):4511-20. Epub 1999/04/14. PubMed PMID: 10201989.
46. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. The Journal of experimental medicine (1994) 180(4):1395-403. Epub 1994/10/01. PubMed PMID: 7523571; PubMed Central PMCID: PMC2191697.
47. Nandagopal N, Ali AK, Komal AK, Lee SH. The Critical Role of IL-15-PI3K-mTOR Pathway in Natural Killer Cell Effector Functions. Front Immunol (2014) 5:187. doi: 10.3389/fimmu.2014.00187. PubMed PMID: 24795729; PubMed Central PMCID: PMC4005952.
48. Kunikata T, Torigoe K, Ushio S, Okura T, Ushio C, Yamauchi H, et al. Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody. Cellular immunology (1998) 189(2):135-43. doi: 10.1006/cimm.1998.1376. PubMed PMID: 9790727.
49. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC, Jr., Abraham RT. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. The EMBO journal (1996) 15(19):5256-67. PubMed PMID: 8895571; PubMed Central PMCID: PMC452270.
50. Powell JD, Delgoffe GM. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity (2010) 33(3):301-11. doi: 10.1016/j.immuni.2010.09.002. PubMed PMID: 20870173; PubMed Central PMCID: PMC2962404.
51. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol (2003) 3(11):900-11. Epub 2003/12/12. doi: 10.1038/nri1226. PubMed PMID: 14668806.
52. Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, et al. Cytokine activation induces human memory-like NK cells. Blood (2012) 120(24):4751-60. doi: 10.1182/blood-2012-04-419283. PubMed PMID: 22983442; PubMed Central PMCID: PMC3520618.
53. Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. Sustained effector function of IL- 12/15/18-preactivated NK cells against established tumors. J Exp Med (2012) 209(13):2351-65. doi: 10.1084/jem.20120944. PubMed PMID: 23209317; PubMed Central PMCID: PMC3526364.
54. Berrien-Elliott MM, Wagner JA, Fehniger TA. Human Cytokine-Induced Memory-Like Natural Killer Cells. Journal of innate immunity (2015). doi: 10.1159/000382019. PubMed PMID: 25924651.
55. Lee SH, Fragoso MF, Biron CA. Cutting Edge: A Novel Mechanism Bridging Innate and Adaptive Immunity: IL-12 Induction of CD25 To Form High-Affinity IL-2 Receptors on NK Cells. J Immunol (2012). Epub 2012/08/14. doi: 10.4049/jimmunol.1201528. PubMed PMID: 22888135.
56. Kim S, Iizuka K, Kang HS, Dokun A, French AR, Greco S, et al. In vivo developmental stages in murine natural killer cell maturation. Nat Immunol (2002) 3(6):523-8. doi: 10.1038/ni796. PubMed PMID: 12006976.
57. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol (2004) 22:405-29. doi: 10.1146/annurev.immunol.22.012703.104711. PubMed PMID: 15032583.
58. Park SY, Saijo K, Takahashi T, Osawa M, Arase H, Hirayama N, et al. Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity (1995) 3(6):771-82. Epub 1995/12/01. PubMed PMID: 8777722.
59. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A (2006) 103(4):1000-5. Epub 2006/01/19. doi: 10.1073/pnas.0507350103. PubMed PMID: 16418296; PubMed Central PMCID: PMC1327727.
60. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood (2002) 100(10):3633-8. doi: 10.1182/blood-2001-12-0293. PubMed PMID: 12393617.
61. Ranson T, Vosshenrich CA, Corcuff E, Richard O, Muller W, Di Santo JP. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood (2003) 101(12):4887-93. Epub 2003/02/15. doi: 10.1182/blood-2002-11-3392. PubMed PMID: 12586624.
62. Biron CA, Turgiss LR, Welsh RM. Increase in NK cell number and turnover rate during acute viral infection. J Immunol (1983) 131(3):1539-45. PubMed PMID: 6886424.
63. Biron CA, Welsh RM. Blastogenesis of natural killer cells during viral infection in vivo. J Immunol (1982) 129(6):2788-95. PubMed PMID: 7142707.
64. McIntyre KW, Natuk RJ, Biron CA, Kase K, Greenberger J, Welsh RM. Blastogenesis of large granular lymphocytes in nonlymphoid organs. Journal of leukocyte biology (1988) 43(6):492-501. PubMed PMID: 2837525.
65. Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei XQ, Liew FY, et al. Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol (2002) 169(8):4279-87. Epub 2002/10/09. PubMed PMID: 12370359.
66. Biron CA, Sonnenfeld G, Welsh RM. Interferon induces natural killer cell blastogenesis in vivo. Journal of leukocyte biology (1984) 35(1):31-7. PubMed PMID: 6200554.
67. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science (2002) 296(5571):1323-6. Epub 2002/04/16. doi: 10.1126/science.1070884. PubMed PMID: 11950999.
68. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, Naidenko OV, et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A (2002) 99(13):8826-31. Epub 2002/06/13. doi: 10.1073/pnas.092258599. PubMed PMID: 12060703; PubMed Central PMCID: PMC124383.
69. Brown MG, Dokun AO, Heusel JW, Smith HR, Beckman DL, Blattenberger EA, et al. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science (2001) 292(5518):934-7. Epub 2001/05/08. doi: 10.1126/science.1060042. PubMed PMID: 11340207.
70. Daniels KA, Devora G, Lai WC, O'Donnell CL, Bennett M, Welsh RM. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. Journal of Experimental Medicine (2001) 194(1):29. PubMed PMID: 112.
71. Lee SH, Girard S, Macina D, Busa M, Zafer A, Belouchi A, et al. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the Ctype lectin superfamily. Nat Genet (2001) 28(1):42-5. Epub 2001/04/28. doi: 10.1038/88247. PubMed PMID: 11326273.
72. Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. Specific and nonspecific N cell activation during virus infection. Nature immunology (2001) 2(10):951-6. Epub 2001/09/1 doi: 10.1038/ni714. PubMed PMID: 11550009.
73. Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, et al. HLA class I subtypedependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol (2009) 83(13):6798-805. doi: 10.1128/JVI.00256-09. PubMed PMID: 19386717; PubMed Central PMCID: PMC2698561.
74. Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood (2004) 104(12):3664-71. doi: 10.1182/blood-2004-05-2058. PubMed PMID: 15304389.
75. Bjorkstrom NK, Lindgren T, Stoltz M, Fauriat C, Braun M, Evander M, et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med (2011) 208(1):13-21. doi: 10.1084/jem.20100762. PubMed PMID: 21173105; PubMed Central PMCID: PMC3023129.
76. Sun JC, Ma A, Lanier LL. Cutting edge: IL-15-independent NK cell response to mouse cytomegalovirus infection. J Immunol (2009) 183(5):2911-4. doi: 10.4049/jimmunol.0901872. PubMed PMID: 19648279; PubMed Central PMCID: PMC2745285.
77. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype Eur J Immunol (1975) 5(2):112-7. Epub 1975/02/01. doi: 10.1002/eji.1830050208. PubMed PMID: 1234049.
78. Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity (2007) 26(6):798-811. Epub 2007/06/02. doi: 10.1016/j.immuni.2007.04.010. PubMed PMID: 17540585.
79. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood (2006) 107(1):159-66. Epub 2005/09/10. doi: 10.1182/blood-2005-04-1351. PubMed PMID: 16150947; PubMed Central PMCID: PMC1895346.
80. Donnelly RP, Loftus RM, Keating SE, Liou KT, Biron CA, Gardiner CM, et al. mTORC1- dependent metabolic reprogramming is a prerequisite for NK cell effector function. J Immunol (2014) 193(9):4477-84. doi: 10.4049/jimmunol.1401558. PubMed PMID: 25261477; PubMed Central PMCID: PMC4201970.
81. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N. mTOR, translation initiation and cancer. Oncogene (2006) 25(48):6416-22. Epub 2006/10/17. doi: 10.1038/sj.onc.1209888. PubMed PMID: 17041626.
82. Loh J, Chu DT, O'Guin AK, Yokoyama WM, Virgin HWt. Natural killer cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in the spleen and liver. J Virol (2005) 79(1):661-7. Epub 2004/12/15. doi: 10.1128/JVI.79.1.661-667.2005. PubMed PMID: 15596864; PubMed Central PMCID: PMC538682.
83. Orange JS, Wang B, Terhorst C, Biron CA. Requirement for natural killer cell-produced interferon gamma in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration. The Journal of experimental medicine (1995) 182(4):1045-56. Epub 1995/10/01. PubMed PMID: 7561678; PubMed Central PMCID: PMC2192290.
84. Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol (1997) 71(1):267-75. Epub 1997/01/01. PubMed PMID: 8985346; PubMed Central PMCID: PMC191047.
85. van Dommelen SL, Sumaria N, Schreiber RD, Scalzo AA, Smyth MJ, Degli-Esposti MA. Perforin and granzymes have distinct roles in defensive immunity and immunopathology. Immunity (2006) 25(5):835-48. Epub 2006/11/08. doi: 10.1016/j.immuni.2006.09.010. PubMed PMID: 17088087.
86. Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu Rev Immunol (2012) 30:39-68. doi: 10.1146/annurev-immunol-020711-075024. PubMed PMID: 22136167; PubMed Central PMCID: PMC3616892.
87. Xu X, Ye L, Araki K, Ahmed R. mTOR, linking metabolism and immunity. Semin Immunol (2012) 24(6):429-35. Epub 2013/01/29. doi: 10.1016/j.smim.2012.12.005. PubMed PMID: 23352227; PubMed Central PMCID: PMC3582734.
88. MacIver NJ, Michalek RD, Rathmell JC. Metabolic regulation of T lymphocytes. Annu Rev Immunol (2013) 31:259-83. doi: 10.1146/annurev-immunol-032712-095956. PubMed PMID: 23298210; PubMed Central PMCID: PMC3606674.
89. Wang R, Green DR. Metabolic reprogramming and metabolic dependency in T cells. Immunol Rev (2012) 249(1):14-26. doi: 10.1111/j.1600-065X.2012.01155.x. PubMed PMID: 22889212; PubMed Central PMCID: PMC3422760.
90. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity (2013) 38(4):633-43. Epub 2013/04/23. doi: 10.1016/j.immuni.2013.04.005. PubMed PMID: 23601682; PubMed Central PMCID: PMC3654249.
91. Pearce EL, Poffenberger MC, Chang CH, Jones RG. Fueling immunity: insights into metabolism and lymphocyte function. Science (2013) 342(6155):1242454. Epub 2013/10/12. doi: 10.1126/science.1242454. PubMed PMID: 24115444.
92. Kidani Y, Elsaesser H, Hock MB, Vergnes L, Williams KJ, Argus JP, et al. Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity. Nat Immunol (2013) 14(5):489-99. doi: 10.1038/ni.2570. PubMed PMID: 23563690; PubMed Central PMCID: PMC3652626.
93. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 12(4):239-52. Epub 2012/03/23. doi: 10.1038/nri3174. PubMed PMID: 22437937.
94. Kalinski P, Mailliard RB, Giermasz A, Zeh HJ, Basse P, Bartlett DL, et al. Natural killerdendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 5(10):1303-15. Epub 2005/10/04. doi: 10.1517/14712598.5.10.1303. PubMed PMID: 16197336.
95. Gascoyne DM, Long E, Veiga-Fernandes H, de Boer J, Williams O, Seddon B, et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol (2009) 10(10):1118-24. doi: 10.1038/ni.1787. PubMed PMID: 19749763.
96. Kashiwada M, Levy DM, McKeag L, Murray K, Schroder AJ, Canfield SM, et al. IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching. Proc Natl Acad Sci U S A (2010) 107(2):821-6. doi: 10.1073/pnas.0909235107. PubMed PMID: 20080759; PubMed Central PMCID: PMC2818942.
97. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Current biology: CB (2009) 19(22):R1046-52. doi: 10.1016/j.cub.2009.09.058. PubMed PMID: 19948145; PubMed Central PMCID: PMC3390254.
98. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 460(7251):108-12. Epub 2009/06/23. doi: 10.1038/nature08155. PubMed PMID: 19543266; PubMed Central PMCID: PMC2710807.
99. Pearce EL, Walsh MC, Cejas PJ, Harms GM, Shen H, Wang LS, et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature (2009) 460(7251):103-7. doi: 10.1038/nature08097. PubMed PMID: 19494812; PubMed Central PMCID: PMC2803086.
100. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity (2010) 32(1):67-78. doi: 10.1016/j.immuni.2009.10.010. PubMed PMID: 20060330.